Paper Details
- Home
- Paper Details
How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials.
Author: DahlöfCarl G H, DodickDavid, DowsonAndrew J, PascualJulio
Original Abstract of the Article :
Almotriptan, the new selective 5-HT1B/1D agonist, has a higher oral bioavailability than any other triptan, with more than two thirds of the administered dose absorbed within the first hour both inside and outside of a migraine attack. Gender or the presence of food in the stomach does not affect it...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1046/j.1526-4610.2002.02025.x
データ提供：米国国立医学図書館（NLM）
Comparing Almotriptan to Other Triptans for Migraine Treatment
Navigating the vast desert of migraine treatment is a challenging journey, often requiring a careful selection of medications to effectively manage debilitating headaches. This review explores the therapeutic efficacy and tolerability of almotriptan, a selective 5-HT1B/1D agonist, in comparison to other triptans. The authors analyze data from placebo-controlled clinical trials, focusing on almotriptan's pharmacokinetic profile, response rates, recurrence rates, and side effects. The review concludes that almotriptan's consistent pharmacokinetics, good efficacy, and excellent tolerability make it a promising option for the acute treatment of migraine attacks.
Almotriptan Offers a Promising Option for Migraine Treatment
This review highlights almotriptan's potential as an effective and well-tolerated treatment for migraine attacks. The authors' analysis of clinical trial data demonstrates that almotriptan provides comparable efficacy to other triptans while offering a favorable pharmacokinetic profile and a low incidence of side effects. The review provides valuable insights for clinicians navigating the challenges of migraine management, offering a promising treatment option for patients seeking relief.
A New Oasis in the Desert of Migraine Treatment
The review offers valuable insights into the potential of almotriptan as a promising treatment for migraine attacks. The authors' analysis of clinical trial data demonstrates that almotriptan provides comparable efficacy to other triptans while offering a favorable pharmacokinetic profile and a low incidence of side effects. The review suggests that almotriptan may offer a valuable oasis in the desert of migraine treatment, providing patients with a potential path to relief from debilitating headaches.
Dr.Camel's Conclusion
This review provides valuable insights into the therapeutic efficacy and tolerability of almotriptan, a selective 5-HT1B/1D agonist, in comparison to other triptans. The authors' analysis of clinical trial data demonstrates that almotriptan provides comparable efficacy to other triptans while offering a favorable pharmacokinetic profile and a low incidence of side effects. The review concludes that almotriptan's consistent pharmacokinetics, good efficacy, and excellent tolerability make it a promising option for the acute treatment of migraine attacks.
Date :
- Date Completed 2002-06-28
- Date Revised 2019-09-01
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.